Analysis
Confido Health has expanded its Series A funding to $22.5 million with a new $12.5 million extension led by Z47 (formerly Matrix Partners India), Pulse 2.0 reported. Healthcare private-equity veteran Justin Saks joined as an investor and board advisor, alongside existing backers Together Fund and Blume Ventures.
Confido's product, CareOS, is an agentic AI operations platform that automates administrative workflows for healthcare organizations -- scheduling, referrals, payer requirements, prescriptions and billing -- integrating with more than 50 systems including EHRs, practice management and fax. The company, led by co-founder and CEO Chetan Reddy, started with AI voice agents and has expanded into back-office operations.
“Provider customers project $10 million to $15 million in annual savings in some deployments.”
Confido says it has grown 15-fold since its previous financing round, with AI handle rates above 95% on critical end-to-end office tasks -- the equivalent of roughly 3 to 5 full-time staff within three months of deployment, per the company. Provider customers project $10 million to $15 million in annual savings in some deployments. The company focuses on multi-site medical groups in ophthalmology, optometry, physical therapy, dental and primary care, including private-equity-backed operators -- a customer base increasingly targeted by healthcare AI vendors looking for standardized workflows across many locations.
Multi-site medical groups are an unusually good fit for this kind of horizontal automation: a private-equity-backed chain of ophthalmology or dental clinics typically runs the same scheduling, billing and payer workflows across dozens of locations, so a single integration can scale across a whole portfolio rather than requiring bespoke work at each site -- a structural advantage over vendors serving single, standalone practices.
However, those savings and handle-rate figures are company-reported and not independently audited, and an extension round -- rather than a new, larger Series A -- suggests investors are adding capital at the existing valuation rather than repricing the company upward. Whether Confido can expand beyond its current specialty niches into higher-volume primary care at the same automation rates will determine if the 15x growth claim scales into a much larger round next time.